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One of the most feared complications of a traditional
pacemaker system is cardiac implantable electronic device
infection. In such cases, a complete removal of the entire
system is recommended.1,2 With the advent of the leadless
transcatheter pacemaker system (TPS), the weak link—
namely, the pacing leads that contribute to this problem—
can be ultimately eliminated. At least 2 major studies have
shown negligible infection rate with the leadless TPS.3–5
Nevertheless, this does not discount the possibility of an
infection ever affecting a TPS. Should that happen, whether
an extraction is warranted is yet to be recommended.6
Some studies on sheep have demonstrated the possibility
of safely extracting the TPS percutaneously.7,8 The ﬁrst-in-
human extraction of a Micra TPS 3 weeks after implantation
owing to elevated capture threshold was recently reported by
Karim et al.9 In this report, we describe the world’s ﬁrst
infected Micra TPS, which eventually led to its extraction
percutaneously 1 month after implantation.Case report
An 80-year-old woman presented with giddiness for 1 week.
She had a background history of hypertension, stroke, and
atrial ﬂutter that was successfully cardioverted. Besides that,
there was also a history of 5-day admission 2 months earlier
for culture-negative urinary tract infection, which was
adequately treated with ciproﬂoxacin. Electrocardiogram
revealed junctional bradycardia (31 beats per minute) at
presentation and atrial ﬁbrillation with rapid ventricular
response the following day. Because she could not tolerate
rate control medication, a decision was made to implant the
Micra TPS ﬁrst and then initiate amiodarone or a beta-
blocker. She received cefazolin at the time of implantation
and another dose 12 hours after implantation, as perKEYWORDS Leadless pacemaker; Transcatheter pacemaker system; Lead
extraction; Infected pacemaker; Micra
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with stable parameters (P wave at 6.3 mV, impedance of 530
ohms, and pacing threshold of 0.88 V at 0.24 ms) on
discharge.
Twenty-two days later, she presented with a week’s
history of lethargy. Pacemaker interrogation demonstrated
an increase in capture threshold from 0.88 V to 1.75 V at
0.24 ms with stable sensing and impedance. Echocardiog-
raphy, electrocardiography, and chest radiograph did
not reveal any signiﬁcant abnormalities. She was then
discharged.
Exactly 1 month after Micra TPS implantation, she
developed fever, chills, and rigors. Methicillin-resistant
Staphylococcus aureus (MRSA) was isolated in 2 separate
blood cultures, for which vancomycin and rifampicin were
initiated. Transesophageal echocardiography (Figure 1)
demonstrated a vegetation (size: 1.2  0.9 cm) that was
attached to the proximal retrieval. Device interrogation
demonstrated a further increase in capture threshold to 4.38
V at 0.24 ms, 3 V at 0.4 ms, and 2.13 V at 1 ms. Pacing
output was increased to 5 V at 0.4 ms. Despite a week of
antibiotics with dosage adjustments based on therapeutic
drug monitoring, blood culture still revealed MRSA. The
subsequent plan was to extract the device percutaneously.
The left femoral vein was punctured (stenosed right
femoral vein) and the 23 French Micra introducer sheath
(Medtronic, Minneapolis, MN) was advanced to the right
atrium, followed by an 8.5 French Agilis NxT medium-curl
steerable sheath (St Jude Medical, Minnetonka, MN) within
it. A 6 French Amplatz GooseNeck Snare (Covidien/
Medtronic, Plymouth, MN) was advanced through a 6
French Multipurpose A1 catheter to provide for a better
support during manipulation (Figure 2A). The proximal
retrieval feature was captured at its waist with the snare
after several attempts (Figure 2B). The device was then
pulled into the introducer sheath with a moderate degree of
counter-traction and the entire system was removed from the
body in 1 piece (Figure 2C and D). There was no pericardial
effusion on echocardiography, which was performed imme-
diately and a day after extraction. Antibiotics were continued
for a further 6 weeks and eventually the blood culture
became negative in 2 separate samples.pen access article under the CC BY-NC-ND license
http://dx.doi.org/10.1016/j.hrcr.2016.04.006
KEY TEACHING POINTS
 Methicillin-resistant Staphylococcus aureus
screening should be performed for all patients prior
to implantation, more so in patients who have a
history of admission within the past 3 months.
 Antibiotic prophylaxis is mandatory for all patients
at the time of implantation, regardless of any
history of infection.
 The Micra transcatheter pacemaker system
extraction technique should be included in the
syllabus when teaching new implanters.
361Koay et al Infected Transcatheter Pacemaker System ExtractionThe extracted device had its proximal retrieval sheath
covered with the vegetation that was observed on trans-
esophageal echocardiography. On its opposite end, a thin
layer of encapsulating tissue that resulted from local ﬁbrous
reaction appeared to be ﬁrmly attached only to all 4 ﬁxation
tines; this was removed, together with the device, during
forceful traction (Figure 3). The device was subsequently
sent for histopathology with particular interest in the
vegetation at the proximal retrieval sheath. The analysis
showed fragments of ﬁbrinous material focally inﬁltrated by
dense neutrophils admixed with few histiocytes, which was
consistent with infected vegetation.Discussion
At 25.9 mm, the Micra TPS is shorter than the lead fragments
retained in the heart following an incomplete extraction in
several experienced centers. Although most of these patients
progressed to complete recovery from infection, it is not
clear how many among them had distal lead endocarditis.7
Bacteremia caused by MRSA, the predominant organisms inFigure 1 Vegetation seen on transesopcardiac implantable electronic device infection, is associated
with high mortality. These organisms form a protective
bioﬁlm on the surface of the Micra device, thus rendering
them antibiotic-resistant. As such, the only intervention to
resolve the infection should be a complete device extraction.
Based on currently available guidelines, a new device can
only be reimplanted no sooner than 2 weeks after the
extraction.10
The proximal retrieval feature of the Micra TPS, which
comprises the docking button and the waist, allows for the
device to be extracted via the over-the-catheter approach
with a snare. Whereas the previous experience with device
extraction demonstrated the ﬁxation tines capture method
with a multiple-loop snare, we demonstrated the proximal
retrieval feature capture method with a single-loop snare.9
The main drawback with our method is the risk of septic
pulmonary embolism while manipulating the snare over the
docking button and tightening the snare around the waist of
the device. However, with careful manipulation and retrac-
tion of the device into the Micra introducer sheath, that risk
can be mitigated.Conclusion
Complete hardware removal is mandatory if elimination of
the infection, especially MRSA, is to be achieved. What
favored a percutaneous over a surgical extraction in this
experience are the modest size of the vegetation (o1.5 cm)
and the duration of implantation (1 month). Despite the
limited worldwide experience, we have safely demonstrated
the management of an infected leadless TPS by percutaneous
extraction. To our knowledge, there are no data pertaining to
the reimplantation of a Micra TPS following an infection.
However, drawing conclusions from current guidelines for
infected lead pacemaker systems, it would seem reasonablehageal echocardiography (arrow).
Figure 2 Steps of the extraction procedure. A: Grandmother-mother-child technique employed to direct the snare at the proximal retrieval feature. B: The
snare is tightened around the waist of the retrieval feature. C: The transcatheter pacing system is retracted toward the introducer sheath. D: The entire system is
pulled out in 1 piece.
Figure 3 The extracted device is seen with the vegetation attached to its
proximal retrieval feature (arrow) and ﬁbrous encapsulation at the ﬁxation
tines.
Heart Rhythm Case Reports, Vol 2, No 4, July 2016362to delay reimplantation of a new Micra TPS for at least 2
weeks after the removal of the infected device.10
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